Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 1
1985 1
1996 1
1998 2
2008 1
2013 2
2014 1
2016 1
2017 2
2019 1
2020 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
[Cerebral toxoplasmosis].
Ribera Pascuet E, López Aldeguer J, Pérez Elías MJ, Podzamczer Palter D. Ribera Pascuet E, et al. Among authors: podzamczer palter d. Enferm Infecc Microbiol Clin. 1998;16 Suppl 1:45-51. Enferm Infecc Microbiol Clin. 1998. PMID: 9859619 Review. Spanish.
[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders].
Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS); Podzamczer Palter D, Muñoz-Moreno JA, Alcolea Rodríguez D, Alonso Villaverde C, Antela López A, Blanch Andreu J, Casado Osorio JL, Galindo Puerto MJ, Garolera i Freixa M, Locutura Rupérez J, Lleó Bisa A, Prats París A, Pérez-Valero I, Portilla Sogorb J, Rovira Cañellas A, Téllez Molina MJ, Tiraboschi JM, Vergara Moragues E, Arribas López JR, Goenaga Sánchez MÁ, de León-Naranjo FL, Martínez Chamorro E, Polo Rodríguez R, Muñoz-Moreno JA, Podzamczer D. Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS), et al. Among authors: podzamczer palter d. Enferm Infecc Microbiol Clin. 2014 Jan;32(1):37-47. doi: 10.1016/j.eimc.2013.03.005. Epub 2013 Apr 30. Enferm Infecc Microbiol Clin. 2014. PMID: 23642283 Spanish.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?
Pérez-Elías MJ, Podzamczer Palter D, Ventayol Bosch P, Jarrín I, Castro A, Rubio-Rodríguez D, Rubio-Terrés C. Pérez-Elías MJ, et al. Among authors: podzamczer palter d. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Dec;40(10):550-556. doi: 10.1016/j.eimce.2021.05.011. Epub 2021 Jul 22. Enferm Infecc Microbiol Clin (Engl Ed). 2022. PMID: 34303633 Free article.
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016.
Moreno S, Antela A, García F, Del Amo J, Boix V, Coll P, Fortuny C, Sirvent JLG, Gutiérrez F, Iribarren JA, Llibre JM, Quirós JCLB, Losa JE, Lozano A, Meulbroek M, Olalla J, Pujol F, Pulido F, Crespo Casal M, García JG, Aldeguer JL, Molina JAP, Podzamczer Palter D, Román AR; Grupo Redactor de GESIDA/SEIMC. Moreno S, et al. Among authors: podzamczer palter d. Enferm Infecc Microbiol Clin. 2017 Jun-Jul;35(6):377-383. doi: 10.1016/j.eimc.2016.11.016. Epub 2017 Feb 22. Enferm Infecc Microbiol Clin. 2017. PMID: 28236498 English, Spanish.
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?
Pérez-Elías MJ, Podzamczer Palter D, Ventayol Bosch P, Jarrín I, Castro A, Rubio-Rodríguez D, Rubio-Terrés C. Pérez-Elías MJ, et al. Among authors: podzamczer palter d. Enferm Infecc Microbiol Clin (Engl Ed). 2021 Jun 30:S0213-005X(21)00190-7. doi: 10.1016/j.eimc.2021.05.006. Online ahead of print. Enferm Infecc Microbiol Clin (Engl Ed). 2021. PMID: 34217551 Free article. English, Spanish.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Walmsley SL, et al. N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541. N Engl J Med. 2013. PMID: 24195548 Free article. Clinical Trial.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. Orrell C, et al. Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Lancet HIV. 2017. PMID: 28729158 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.
17 results